What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
3 years 1 month ago
No clear excess risk for offspring exposed in-utero to, VED or TNFi's. UST showed infection signal BUT w/ wide CIs. We need more research re: biologics and placental transmission potential/subsequent risks. Abs 1713 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/W3K5uDyHlC
David Liew drdavidliew
3 years 1 month ago
b/tsDMARDs + tumor response in rheum irAEs
Excellent point by @CCalabreseDO @LCalabreseDO:
- despite progression in 5/10, DMARD contribution uncertain (bad cancer)
- without DMARD, ICI would have had to stop
crucial question, prospective study needed
#ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH
Dr. Rachel Tate uptoTate
3 years 1 month ago
The wave of the future? Study details immune profile which discriminates PsA from PsO using phenotyping of serum immune cell subsets & machine learning. Abs 1774 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/huNTY3IdRf https://t.co/3aW64pb9UW
TheDaoIndex KDAO2011
3 years 1 month ago
Great case where the #COVIDvaccine was blamed, but he had a diet of doughnuts, steak&cheese sandwiches w/snack cakes, and popsicles. #ThievesMarket #ACR21 @rheumnow https://t.co/J78Nw5NhKs
Dr. John Cush RheumNow
3 years 1 month ago
The #ACR21 Playbook
This playbook is designed to help you navigate a truly big meeting (with >2000 presentations and over 15,000 attendees from over 100+ countries). What follows is based on experience and the acquired insights our peers.
https://t.co/GlDOnVfHsc https://t.co/RQlM2fjCzY
David Liew drdavidliew
3 years 1 month ago
Autoantibodies are underrated in rheumatic irAEs (?B cells in general), but probably not your usual.
If Ab are of interest, suspect we're going to have to look at non-classical ones
Elegant from @NilashaGhosh @MPostow @got_rheum @lovetolearn27 #ACR21 ABST1520 ABST1521 @RheumNow https://t.co/tLSJOZw1YG
Eric Dein ericdeinmd
3 years 1 month ago
Great conversation with @BayviewMedicine @jhrheumatology alum Dr. Jason Liebowitz and Professor Janet Zeide on "Gift of Gab"- communications skills for the rheumatologist at #ACR21! @Rheumnow https://t.co/O1u3X8urag
Olga Petryna DrPetryna
3 years 1 month ago
Abst1783 #ACR21 #ACRBest @RheumNow Canadian study reports promising trends on hospitalizations for serious infections in PsA: 2012 – 2017 statist signif ⬇️ in discharges for sepsis, skin & soft tissue infect & UTI (p < 0.001 for all). no statistical difference in the trend of PNA https://t.co/lqtCzUFPAW
Richard Conway RichardPAConway
3 years 1 month ago
We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2
Robert B Chao, MD doctorRBC
3 years 1 month ago
Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement
⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics
#ACR21 @RheumNow
Abs#1802
https://t.co/QvyayelBYU https://t.co/50dNQm30vf
David Liew drdavidliew
3 years 1 month ago
How do RA pts go with ICI cancer therapy?
@VUMCRheum audit reflects overall prev experience:
- approx 50% flare (?some reflect DMARD W/H)
- flares overwhelmingly managable
- few (1/19 here) cease ICI due to RA flare
RA pts deserve best cancer Rx too!!
#ACR21 ABST1523 @RheumNow
Janet Pope Janetbirdope
3 years 1 month ago
Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416
sheila RHEUMarampa
3 years 1 month ago
Dr. Despotovic shares general principles about ICU admissions in patients w/ #rheumatic disease.
🔺#SLE, RA, systemic #vasculitis, SSc, IIMs
🔺serologic testing useful but interpret w/n clinical context
@RheumNow #ACR21 https://t.co/jb3Mt31dZz
Poster Hall